NewswireToday Leading Press Releases & Newswire Distribution Service

Genentech, Inc. Company Profile & Social Media Wall Press Room - Press Releases

Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

	Company Name:	Genentech, Inc.
	Trading Symbol(s):	[SIX: RO, ROG; OTCQX: RHHB]
	Contact:	Press Office - Gene.com
	Address:	Confidential
	City:	San Francisco
	Zip code:	94080
	STATE / Prov.:	CA
	Country:	United States
	Primary Industry:	Pharma / BioTech / Nutrition
	PR Agency:	No

Your Company Advertising Here!
Showing along with this industry
- Learn more...

Latest Articles:
FDA Grants Priority Review to Genentech’s Risdiplam for Spinal Muscular Atrophy - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Rozlytrek (entrectinib) for People With ROS1-Positive, Metastatic Non-small Cell Lung Cancer - [ Pharma / BioTech / Nutrition ]
Genentech Announces Positive Results for First Global Phase III Study Investigating One-dose XOFLUZA (Baloxavir Marboxil) in Children With the Flu - [ Pharma / BioTech / Nutrition ]
FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers - [ Pharma / BioTech / Nutrition ]
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Tecentriq in Combination with Avastin and Chemotherapy - [ Pharma / BioTech / Nutrition ]
FDA Approves Label Update for Genentech’s Rituxan (Rituximab) in Two Rare Forms of Vasculitis - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Avastin (Bevacizumab) Plus Chemotherapy as a Treatment for Women with Advanced Ovarian Cancer Following Initial Surgery - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris - [ Pharma / BioTech / Nutrition ]
Genentech to Present New Phase III Data for HEMLIBRA in People with Hemophilia A at the World Federation of Hemophilia 2018 World Congress - [ Pharma / BioTech / Nutrition ]
Genentech to Present New Data at AAN Highlighting Extensive Research for Ocrevus and Expanding Neuroscience Pipeline - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg Prefilled Syringe for Diabetic Macular Edema and Diabetic Retinopathy - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Hemlibra (Emicizumab-kxwh) for Hemophilia A with Inhibitors - [ Pharma / BioTech / Nutrition ]
FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation - [ Pharma / BioTech / Nutrition ]
New OCREVUS (Ocrelizumab) Data at ECTRIMS Advance Clinical Understanding of Underlying Progression in Multiple Sclerosis - [ Pharma / BioTech / Nutrition ]
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome - [ Pharma / BioTech / Nutrition ]
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma - [ Pharma / BioTech / Nutrition ]
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors - [ Pharma / BioTech / Nutrition ]
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation - [ Pharma / BioTech / Nutrition ]
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis - [ Pharma / BioTech / Nutrition ]
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy - [ Pharma / BioTech / Nutrition ]
FDA Grants Breakthrough Therapy Designation for Rituxan® (Rituximab) in Pemphigus Vulgaris - [ Pharma / BioTech / Nutrition ]
FDA Grants Genentech’s Cancer Immunotherapy Tecentriq® (Atezolizumab) Priority Review in Additional Type of Advanced Bladder Cancer - [ Pharma / BioTech / Nutrition ]

Next Page »

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business

See your Ad Here!

PREMIUM Members

- See your Logo Here! -